BARBADOS INCIDENCE STUDY OF EYE DISEASES II
巴巴多斯眼病发病率研究 II
基本信息
- 批准号:2430372
- 负责人:
- 金额:$ 105.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-09-30 至 2002-06-30
- 项目状态:已结题
- 来源:
- 关键词:African Caribbean aging alcoholism /alcohol abuse blindness cardiovascular disorder cataract clinical research cooperative study diabetes mellitus diabetic retinopathy dietary supplements disease /disorder etiology disease /disorder proneness /risk epidemiology eye disorder diagnosis eye fundus photography eye refractometry family genetics gene environment interaction glaucoma glaucoma test human middle age (35-64) human old age (65+) human population study human subject hypertension interview longitudinal human study macular degeneration nutrition related tag pathologic process statistics /biometry tobacco abuse vision tests visual fields visual perception
项目摘要
The proposed Barbados Incidence Study of Eye Diseases II (BISED II) aims
to collect 9-year incidence and progression data on open-angle glaucoma
(OAG) and age-related cataract in the predominantly black population of
Barbados, West Indies, as well as to obtain natural history data on age-
related macular changes and diabetic changes. OAG and cataract are the two
major causes of blindness in populations of African origin, accounting for
about half of visual loss. Despite their high prevalence and public health
importance, data on blacks are limited and no clear explanation for the
increased risk exists. Early macular changes were frequent in the BES.
Although diabetic retinopathy was less common, about one-fifth of the
population has diabetes, thus raising questions about risk factors for DR
in a black population. BISED II provides a unique opportunity to obtain
the first long term incidence and progression data on a large population-
based cohort, as such longitudinal data are not available for black
populations. BISED II will provide new information concerning natural
history and underlying factors for these chronic, life-long eye diseases,
to assist in understanding etiology, identifying groups at high risk, and
developing strategies to control visual loss. A shorter follow-up is
insufficient to provide this information. To achieve these aims, BISED II
will re-examine the surviving cohort of the Barbados Eye Study (BES). The
BES was conducted from 1988 to 1992 to measure prevalence and risk factors
for OAG, cataract, age-related macular degeneration and diabetic
retinopathy, while providing baseline data for further incidence
measurements. The BES was followed by the Barbados Incidence Study of Eye
Diseases (BISED; 1992-1997), which is determining 4-year incidence and
progression for these conditions. High participation rates of 84% and 85%
were achieved by BES and BISED, respectively, among the eligible cohort.
The positive response of the cohort and the past experience gained in
conducting BES and BISED enhance the feasibility of successful follow-up.
Given the cohort size, follow-up rates of incidence and progression can be
estimated with high precision. Given the high prevalence and incidence, a
wide range of relative risks can be detected. In summary, the BES cohort
is a unique resource to study the major causes of blindness and provides
an opportunity to learn, for the first time, about their long-term
patterns of occurrence in a black population. This information may assist
to address major racial differences in prevalence and has important public
health implications.
拟议的巴巴多斯眼病发病率研究 II (BISED II) 的目标
收集开角型青光眼 9 年的发病率和进展数据
(OAG) 和以黑人为主的人口中与年龄相关的白内障
巴巴多斯、西印度群岛,以及获得有关年龄的自然历史数据
相关的黄斑变化和糖尿病变化。 OAG和白内障是两个
非洲裔人群失明的主要原因,占
大约一半的视力丧失。尽管其患病率很高且公共卫生
重要性,关于黑人的数据有限,并且没有明确的解释
存在增加的风险。 BES 中早期黄斑变化很常见。
尽管糖尿病视网膜病变不太常见,但大约五分之一的人患有糖尿病视网膜病变。
人口患有糖尿病,因此引发了关于 DR 危险因素的疑问
在黑人人口中。 BISED II 提供了一个独特的机会来获得
第一个针对大量人群的长期发病率和进展数据-
基于队列,因为此类纵向数据不适用于黑人
人口。 BISED II 将提供有关自然的新信息
这些慢性、终生眼病的病史和潜在因素,
协助了解病因、识别高危人群,以及
制定控制视力丧失的策略。较短的后续行动是
不足以提供此信息。为了实现这些目标,BISED II
将重新检查巴巴多斯眼科研究(BES)的幸存队列。这
BES 于 1988 年至 1992 年间进行,旨在衡量患病率和风险因素
用于 OAG、白内障、年龄相关性黄斑变性和糖尿病
视网膜病变,同时为进一步的发病率提供基线数据
测量。 BES 之后进行了巴巴多斯眼病发病率研究
疾病(BISED;1992-1997),确定 4 年发病率和
这些条件的进展。参与率高达 84% 和 85%
BES 和 BISED 分别在符合条件的队列中实现了这一目标。
群体的积极反应和过去获得的经验
开展 BES 和 BISED 增强了成功后续行动的可行性。
考虑到队列规模,发病率和进展的随访率可以
估计精度很高。鉴于患病率和发病率较高,
可以检测到广泛的相对风险。总之,BES 队列
是研究失明主要原因的独特资源,并提供
第一次了解他们的长期发展的机会
黑人群体中的发生模式。此信息可能会有所帮助
解决患病率方面的主要种族差异,并具有重要的公众意义
健康影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MCRISTINA LESKE其他文献
MCRISTINA LESKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MCRISTINA LESKE', 18)}}的其他基金
BARBADOS FAMILY STUDY OF OPEN-ANGLE GLAUCOMA (BFSG)
巴巴多斯开角型青光眼家庭研究 (BFSG)
- 批准号:
2165222 - 财政年份:1994
- 资助金额:
$ 105.1万 - 项目类别:
BARBADOS FAMILY STUDY OF OPEN-ANGLE GLAUCOMA (BFSG)
巴巴多斯开角型青光眼家庭研究 (BFSG)
- 批准号:
2545873 - 财政年份:1994
- 资助金额:
$ 105.1万 - 项目类别:
BARBADOS FAMILY STUDY OF OPEN-ANGLE GLAUCOMA (BFSG)
巴巴多斯开角型青光眼家庭研究 (BFSG)
- 批准号:
2356479 - 财政年份:1994
- 资助金额:
$ 105.1万 - 项目类别:
BARBADOS FAMILY STUDY OF OPEN-ANGLE GLAUCOMA (BFSG)
巴巴多斯开角型青光眼家庭研究 (BFSG)
- 批准号:
6153262 - 财政年份:1994
- 资助金额:
$ 105.1万 - 项目类别:
BARBADOS FAMILY STUDY OF OPEN-ANGLE GLAUCOMA (BFSG)
巴巴多斯开角型青光眼家庭研究 (BFSG)
- 批准号:
2165221 - 财政年份:1994
- 资助金额:
$ 105.1万 - 项目类别:
DATA COORDINATING CENTER FOR EARLY GLAUCOMA TRIAL
早期青光眼试验数据协调中心
- 批准号:
2467532 - 财政年份:1993
- 资助金额:
$ 105.1万 - 项目类别:
DATA COORDINATING CENTER FOR EARLY GLAUCOMA TRIAL
早期青光眼试验数据协调中心
- 批准号:
2164008 - 财政年份:1993
- 资助金额:
$ 105.1万 - 项目类别:
相似海外基金
Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
- 批准号:
24K18114 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
- 批准号:
10089306 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Collaborative R&D
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
- 批准号:
498288 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
- 批准号:
23K20339 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Operating Grants
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
- 批准号:
2740736 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Studentship
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
- 批准号:
2406592 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Standard Grant
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
- 批准号:
2305890 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Fellowship Award
虚弱高齢者のSuccessful Agingを支える地域課題分析指標と手法の確立
建立区域问题分析指标和方法,支持体弱老年人成功老龄化
- 批准号:
23K20355 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
「ケア期間」に着目したbiological aging指標の開発
开发聚焦“护理期”的生物衰老指数
- 批准号:
23K24782 - 财政年份:2024
- 资助金额:
$ 105.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




